Stock Price & Analysis

Based on the current analysis, buy Blueprint Medicines (BPMC) as it has a Moderate Buy consensus with a favorable price target and positive technical indicators.

Price Prediction for BPMC Stock in 2025

The price prediction for Blueprint Medicines Corp (BPMC) stock in 2025 is expected to reach $127.23, driven by strong analyst consensus and positive fundamentals.

• Analyst Consensus: The average price target from analysts is $127.23, with a high estimate of $155.00 and a low of $119.00. This reflects a 40.2% upside from current levels.
• Technical Indicators: The stock is currently trading near its Fibonacci pivot level of $90.47, with RSI levels indicating potential upside momentum.
• Fundamental Growth: Blueprint Medicines' focus on precision therapies and strong pipeline growth supports its bullish outlook.

The S1 support level for BPMC Stock is $85.67 ,The R1 resistant level for BPMC Stock is $94.94.

As of the end of day on 2025-03-14, the price of BPMC Stock was $90.01.

The target price for BPMC Stock according to analyst rating is 129.46, with the highest price target at 155.00 and the lowest at 105.00. Analysts have a Moderate Buy rating on BPMC Stock overall.

The market cap of BPMC is $5.7B.

Analysis and Insights

To determine if Blueprint Medicines (BPMC) is overvalued, we analyze its financial metrics and market sentiment.

Valuation Metrics:

BPMC's valuation metrics indicate a premium. The price-to-sales (PS) ratio is 20.66, and the price-to-book (PB) ratio is 19.11, both significantly higher than industry averages, suggesting overvaluation.

Financial Performance:

While revenues have grown steadily, net income remains negative, indicating ongoing operational losses. Gross margins are strong, around 96-98%, showing efficient cost control.

Analyst Sentiment:

Analysts maintain a Moderate Buy consensus with a $127.23 average price target, reflecting a 33.9% upside. This suggests potential but may not fully justify current valuations.

{RATING:symbol=BPMC.O, type=0}

Conclusion:

BPMC's high PS and PB ratios, coupled with negative net income, suggest overvaluation. However, increasing revenues and strong margins indicate growth potential. Analysts remain cautiously optimistic.

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Price Prediction for BPMC Stock by 2030

Based on current trends and analyst expectations, Blueprint Medicines Corp (BPMC) is projected to reach a stock price of $175 by 2030. This prediction is supported by the company's strong pipeline of precision therapies, including AYVAKIT and GAVRETO, and its focus on oncology and inflammatory diseases. Analysts have set an average price target of $127.23, with some firms like Stifel predicting up to $155, indicating confidence in the company's growth potential.

BPMC has a total of 655 employees.